MediPharm Labs Corp.

OTCPK:MEDI.F Stock Report

Market Cap: US$23.7m

MediPharm Labs Past Earnings Performance

Past criteria checks 0/6

MediPharm Labs's earnings have been declining at an average annual rate of -14.6%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been declining at an average rate of 25.9% per year.

Key information

-14.6%

Earnings growth rate

0.4%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate-25.9%
Return on equity-24.7%
Net Margin-39.6%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How MediPharm Labs makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:MEDI.F Revenue, expenses and earnings (CAD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2333-13200
30 Sep 2330-16230
30 Jun 2328-19221
31 Mar 2323-26211
31 Dec 2222-30241
30 Sep 2222-46322
30 Jun 2220-46322
31 Mar 2221-48321
31 Dec 2122-55312
30 Sep 2122-64222
30 Jun 2122-72231
31 Mar 2130-63252
31 Dec 2036-66282
30 Sep 2062-39352
30 Jun 20101-20352
31 Mar 20118-15332
31 Dec 191292311
30 Sep 191071220
30 Jun 1964-4170
31 Mar 1932-8120
31 Dec 1810-860
30 Sep 180-640
30 Jun 180-430
31 Mar 180-220
31 Dec 170-110

Quality Earnings: MEDI.F is currently unprofitable.

Growing Profit Margin: MEDI.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: MEDI.F is unprofitable, and losses have increased over the past 5 years at a rate of 14.6% per year.

Accelerating Growth: Unable to compare MEDI.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MEDI.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).


Return on Equity

High ROE: MEDI.F has a negative Return on Equity (-24.68%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.